View document text
18th November, 2026
Corporate Relationship Department Manager – Listing
M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd
Mumbai 400 001 Mumbai 400 051
Scrip Code: 524816 Scrip Code: NATCOPHARM
Dear Sir/Madam,
Sub:- Transcript of earnings conference call held on 13th November, 2026
Ref:- Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements),
Regulations, 2015
We are enclosing herewith the copy of transcript of the Company's earnings conference
call for Q2 FY26-27 held on 13th November, 2026. The transcript is also available on the
website of the Company at https://www.natcopharma.co.in/investor-relations/financials-
filings.
This is for your information and records
Thanking you
Yours faithfully
For NATCO Pharma Limited
Ch. Venkat Ramesh
Company Secretary &
Compliance Officer
NATCO Pharma Limited - Earnings Call – Q2FY27
November 13, 2026
- Moderator:
- Ladies and gentlemen, good day and welcome to NATCO Pharma Limited's Earnings
Conference Call for the 2nd Quarter FY27. We have with us on the call Mr. Rajeev
Nannapaneni - Vice Chairman and CEO, Mr. Amit Parekh - Chief Financial Officer, Mr.
Rajesh Chebiyam - Executive Vice President, Crop Health Sciences and Mr. Rajeev Menon,
Lead Investor Relations.
- Please note that all Analysts' lines will be in listen-only mode, and there will be an
opportunity for you to ask questions after management's opening remarks. Should you
need any assistance during the conference call, please raise your hand from the Analyst
tab on the screen. While asking questions, please identify yourself and your company.
Please note that this conference is being recorded.
- I now hand over the call to Mr. Rajeev Menon. Thank you, and over to you, sir.
- Mr. Rajeev Menon - Lead Investor Relations, NATCO Pharma Limited:
- Thank you, Vandit. Good evening and welcome everyone to NATCO's Conference Call
discussing our earnings result for the 2nd Quarter of FY27. I am Rajeev Menon, Lead
Investor Relations at NATCO. We hope you have received the earnings presentation and
press release that was sent out earlier. Let me draw your attention to the fact that on this
call we may be making certain forward-looking statements which are not necessarily
historical facts. And anything said on this call which reflects our outlook for the future
must be reviewed in conjunction with the risk that the company faces. We undertake no
obligations to update these forward-looking statements. I would like to state that the
material of the call except for Analyst questions is a property of NATCO and cannot be
recorded or rebroadcasted without NATCO's express written permission. We will begin
with the financial highlights and then follow with an interactive Q&A session. With that, I
request our CFO, Amit Parekh to discuss the financial highlights. Over to you, sir.
- Mr. Amit Parekh - CFO, NATCO Pharma Limited:
- Thank you, Menon. Greetings to everyone and thank you once again for joining us in
today's Earnings Call.
- The company recorded consolidated total revenues of ₹1,019.4 crores in Q2FY27
compared to ₹794 crores in Q1 of FY27 and ₹1,463 crores in the corresponding quarter
of the previous year. The quarter-on-quarter increase was primarily driven by the strong
performance of our international formulation business. The Y-o-Y decline was largely
attributable to lower lenalidomide revenue during the quarter, which was partially offset
by the growth in the base business which also includes our subsidiaries. EBITDA including
other income for the quarter stood at ₹310 crores, with EBITDA margin of 30.4%.
Consolidated profit after tax stood at ₹202.6 crores compared to ₹206.5 crores in Q1
FY27.
- With regards to our associate company Adcock Ingram Holding Limited, South Africa, the
revenue for the quarter stood at ₹1,344 crores and profit after tax at ₹80.5 crores. In July
2026, we acquired additional 13.25% stake in Adcock Ingram Holding Limited, taking our
total holdings to 49%. This further strengthens our strategic position in South African
market and enhances our participation in the performance of Adcock Ingram. NATCO's
share of profit based on 49% holding as on 30th of September 2026 was ₹29.2 crores after
adjustment relating to purchase price allocation. Our domestic formulation business
revenue stood at ₹145 crores. We also saw strong growth in our Brazil business. Revenue
from Brazil stood at ₹121 crores, representing the growth of 66%.
- Thank you all. With this, we will take question and answer. Over to you.
- Moderator:
- Thank you, sir. We will now open the call for Q&A session. We will wait for few minutes
until the queue assembles. We request Analysts to respond to 2 questions and then
return to the queue for more questions. Requesting to please introduce yourself and your
company before asking the question. Please raise your hand from the Analyst tab on the
screen to ask the question. We will wait for couple of minutes for Analysts to raise their
hands and ask the question.
- The first question is from Shekhar Jain.
- Mr. Shekhar Jain - Individual Investor:
- Yeah, I am an individual investor. So, I had two questions.
- In March, when we announced that we have first-to-file status for Pomalidomide, I was
hoping for a bit of a bump. So, what happened with the Pomalidomide first-to-file status?
- And the second question is, what do we plan to do with the rights issue proceeds? Any
colour on that will be very helpful.
- Mr. Rajeev Nannapaneni - Vice Chairman & CEO, NATCO Pharma Limited:
- First question was on Pomalidomide. We did get the first-to-file, Shekhar. But it is a shared
first-to-file. I don’t remember the exact number of generic competitors. I think about 5 to
6 generic competitors came in the first wave. Because there were 5 and 6 competitors,
the price erosion was quite steep. So, even though we had 180 days, the earnings bump
was not too substantial that could move the earnings. It is the way it is. That is the nature
of business.
- The second question is on the rights. So, I think we have multiple end-use requirements.
I think primarily it is to reduce the debt that we have raised for Adcock. We are also
keeping some money for the possible acquisition. We are looking at various acquisitions.
So, that is the end-use expectation.
- Moderator:
- The next question is from Bhuvanesh Bhoomi.
- Mr. Bhuvanesh Bhoomi - Individual Investor:
- My name is Bhuvanesh. I am an individual investor.
- So, I think as of now, Revlimid sales is exhausted. So, what is the next big shot drug in our
pipeline?
- Mr. Rajeev Nannapaneni - Vice Chairman & CEO, NATCO Pharma Limited:
- Next big, I think we have a few launches that are coming up in the next few quarters. For
one is definitely Carfilzomib launch is there. It is coming up in the next few quarters. And
of which one strength we have first-to-file. 60 mg is shared first-to-file and then we have
Trabectedin coming up, which is a smaller product. But we are one among the two first-
to-file. Then we have, these are 2 major ones in the US and then we are expecting launch
of Olaparib also in the next few quarters in Brazil and Canada. So, these are the major
launches coming up in the coming few quarters subject to launch and legal challenge.
- Mr. Bhuvanesh Bhoomi - Individual Investor:
- And sir, what's the plan about spinning of our Agri-fertilizer business going forward?
- Mr. Rajesh Chebiyam - Executive Vice President Crop Health Sciences, NATCO Pharma
Limited:
- See, as you are aware, we did a rights issue, which basically what it does also the capital
structure is now changed a bit. Because of that, we have to resubmit the file to SEBI. So,
it pushes out by 4 to 6 months from the original plan. So, we're looking at maybe by mid-
year, calendar year next year is when we hope to get the demerger done.
- Mr. Bhuvanesh Bhoomi - Individual Investor:
- Yeah. Thank you, sir.
- Moderator:
- Thank you. The next question is from Ramakrishnan.
- What are the plans regarding th
[Showing first 8,000 characters — download PDF for full document]